Cognitive Impairment in Major Depressive Disorder as a Target for Drug Development

Chairs: Thomas Laughren, Catherine Harmer

This session will cover the scientific basis for considering CI in MDD as an unmet need and legitimate entity for drug development, and also important methodological issues such as optimal assessment approaches, study design, and when in the illness to study CI.  Also provided will be an industry perspective from a representative of a company that has approached this target, and also regulatory perspectives.